At an all-day meeting for investors last month in a posh Manhattan event space, executives at Merck couldn’t have been more excited about a new HIV drug, MK-8591. They mentioned it 25 times, calling it “a game changer” and talking up its “remarkable properties.”
Why? If effective, it could be used in a new drug combination that might have fewer side effects, the company says. More excitingly, it might be fashioned into an implant that could be given only once a year to prevent patients at high risk from contracting HIV, a boon to public health.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
You know thousands of babies are born HIV positive, right? You’re in favor of punishing them too?